Methylenetetrahydrofolate reductase (MTHFR) is a pivotal enzyme in the folate metabolic pathway, catalyzing the irreversible conversion of 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate. This reaction is the rate-limiting step in the methyl cycle, directing folate cofactors toward the remethylation of homocysteine to methionine. Genetic polymorphisms in MTHFR (specifically C677T and A1298C) are widely studied due to their association with hyperhomocysteinemia, cardiovascular disease, neural tube defects, and altered sensitivity to antifolate chemotherapies. In oncology and metabolic disease R&D, targeting MTHFR represents a strategic approach to modulating cellular methylation potential and synergizing with existing folate antagonists.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for MTHFR drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | MTHFR Recombinant Protein (Wild-Type & C677T/A1298C Mutants) High purity (>95%), Endotoxin Controlled, Sequence Verified, Theoretical MW confirmed. |
View MTHFR Products |
| Gene Delivery | MTHFR Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and overexpression assays. |
View MTHFR Products |
| Benchmark Ab | Anti-MTHFR Recombinant Antibody High-affinity sequence-derived positive control for Western Blot and ELISA. |
View MTHFR Products |
| Validator | MTHFR siRNA Set Target-specific knockdown verification to confirm phenotype specificity. |
View MTHFR Products |
| Related Target A | DHFR (Dihydrofolate Reductase) Key upstream enzyme in the folate pathway; critical for cross-reactivity and selectivity profiling. |
View DHFR Products |
| Related Target B | TYMS (Thymidylate Synthase) Downstream folate-dependent enzyme; essential for evaluating pathway-wide metabolic disruption. |
View TYMS Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Polymorphism-specific drug screening (C677T vs. WT) | Recombinant Wild-Type and Mutant MTHFR proteins strictly sequence-verified with high purity (>95%). |
| Folate pathway off-target profiling | Homolog panel including high-purity DHFR and TYMS recombinant proteins for selectivity assays. |
| Lack of reliable positive controls | Clinical-grade recombinant benchmark antibodies included for assay standardization. |
| Off-target phenotype validation | Sequence-specific siRNA knockdown sets included for rigorous target validation. |
Live MTHFR R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of MTHFR is expanding beyond its traditional role as a genetic biomarker. Current drug discovery efforts are shifting toward small-molecule inhibitors and allosteric modulators designed to selectively disrupt folate metabolism in rapidly proliferating cancer cells. As first-generation antifolates face resistance challenges, the next wave of R&D targets MTHFR both as a direct therapeutic node and as a synthetic lethal partner in tumors with specific metabolic vulnerabilities (such as MTAP deficiency or high homocysteine dependency).
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Academic Institutes, Oncology Biotechs | Solid Tumors, Hematological Malignancies | Selectivity Assay (Need Mutant vs. WT Proteins to evaluate polymorphism susceptibility) |
| Allosteric Modulators | Metabolic Disease Specialists | Hyperhomocysteinemia, Cardiovascular Disorders | Conformational Stability Assay (Need High-Purity, Native-folded HEK293 expressed proteins) |
| Combination Therapies | Global Pharmaceutical Developers | Chemo-resistant Cancers (Methotrexate adjuvant) | Pathway Validation (Need MTHFR, DHFR, and TYMS knockdown tools like siRNA and Lentivirus) |